BRD9激活神经元中的转录,而BRD9抑制剂阻断了小鼠的行为
Mengmeng Shi1, Meng Wang2, Dan Luo3
1Department of Human Anatomy, Hengyang Medical School, University of South China, Hengyang, 421001, Hunan, China; Department of Basic Medicine, Medical School, Xiangyang Polytechnic, Xiangyang, 441000, Hubei, China.
European journal of pharmacology
|August 31, 2025
概括
No abstract available in PubMed .
相关概念视频
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
445
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
445
Epilepsy and Seizures: Overview
275
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
275


